BML Capital Management LLC Invests $686,000 in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

BML Capital Management LLC bought a new position in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 653,107 shares of the biotechnology company’s stock, valued at approximately $686,000. Aclaris Therapeutics accounts for about 0.5% of BML Capital Management LLC’s holdings, making the stock its 26th largest holding. BML Capital Management LLC owned approximately 0.92% of Aclaris Therapeutics at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the business. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Aclaris Therapeutics by 42.6% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 20,317 shares of the biotechnology company’s stock worth $139,000 after buying an additional 6,074 shares during the period. Corton Capital Inc. acquired a new stake in Aclaris Therapeutics in the third quarter valued at about $102,000. Vontobel Holding Ltd. lifted its position in Aclaris Therapeutics by 128.8% in the fourth quarter. Vontobel Holding Ltd. now owns 30,268 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 17,040 shares during the period. SG Americas Securities LLC lifted its position in Aclaris Therapeutics by 20.1% in the third quarter. SG Americas Securities LLC now owns 151,704 shares of the biotechnology company’s stock valued at $1,039,000 after purchasing an additional 25,357 shares during the period. Finally, Vanguard Group Inc. lifted its position in Aclaris Therapeutics by 1.0% in the third quarter. Vanguard Group Inc. now owns 3,363,046 shares of the biotechnology company’s stock valued at $23,037,000 after purchasing an additional 33,482 shares during the period. Institutional investors and hedge funds own 98.34% of the company’s stock.

Aclaris Therapeutics Stock Performance

Shares of Aclaris Therapeutics stock opened at $1.22 on Wednesday. Aclaris Therapeutics, Inc. has a 12-month low of $0.59 and a 12-month high of $11.12. The stock has a market cap of $86.53 million, a PE ratio of -0.96 and a beta of 0.22. The company has a 50-day moving average of $1.22 and a two-hundred day moving average of $1.84.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.07. Aclaris Therapeutics had a negative net margin of 283.15% and a negative return on equity of 64.56%. The business had revenue of $17.57 million during the quarter, compared to analysts’ expectations of $3.96 million. On average, sell-side analysts forecast that Aclaris Therapeutics, Inc. will post -0.98 EPS for the current fiscal year.

Analyst Ratings Changes

ACRS has been the subject of a number of recent analyst reports. Cantor Fitzgerald restated a “neutral” rating on shares of Aclaris Therapeutics in a research report on Friday, January 12th. BTIG Research restated a “neutral” rating on shares of Aclaris Therapeutics in a research report on Thursday, January 11th. StockNews.com cut shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, April 2nd. Finally, HC Wainwright cut shares of Aclaris Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday, January 22nd. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $22.25.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.